Oracle Runs

Will the results be positive?

Trial completed per sponsor 10-K (LPLV Q4 2025), but no public readout available as of Apr 2026. Sponsor expects to announce results in Q2 2026. No press releases, investor updates, or clinicaltrials.gov results found framing outcomes positively or negatively. Evidence incomplete.

Will the results be positive?

No public readout available. LPLV Q4 2025; results expected Q2 2026 per sponsor filings. Primary endpoints are PK parameters (AUCtau, Cmax), not efficacy. No sources report positive/negative framing for this exact trial.

Will the results be positive?

ClinicalTrials.gov lists this study as completed but without posted results, so there is no clear public trial-specific basis yet to call the readout positive or negative.

Will the results be positive?

No trial-specific public efficacy/PK readout was found. The sponsor said in February 2026 that NCT06576843 results are expected in Q2 2026, which was still in the future as of April 3, 2026. ClinicalTrials.gov identifies the study and endpoints but does not provide an interpretive outcome readout here.

Will the results be positive?

No trial-specific public efficacy readout was found. Public sources show NCT06576843 completed/updated, but as of early 2026 the sponsor was still only describing it as a Phase 2 PK/safety/tolerability study, and a results-tracking page indicates no results were posted. That is insufficient to call positive or negative.